|
All Clinical trials
Citations 11-20 of 604 total displayed.
|
Past content
(since Jan 2000):
|
- ARTICLES
Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs)
- W. N. Kernan, C. M. Viscoli, D. DeMarco, B. Mendes, K. Shrauger, J. L. Schindler, J. C. McVeety, A. Sicklick, D. Moalli, P. Greco, D. M. Bravata, S. Eisen, L. Resor, K. Sena, D. Story, L. M. Brass, K. L. Furie, L. Gutmann, E. Hinnau, M. Gorman, A. M. Lovejoy, S. E. Inzucchi, L. H. Young, R. I. Horwitz On behalf of the IRIS Trial Investigators
Neurology 2009; 72: 1345-1351.
[Abstract]
[Full text]
[PDF]
- VIEWS AND REVIEWS
Multiple sclerosis therapeutics: Unexpected outcomes clouding undisputed successes
- Heinz Wiendl and Reinhard Hohlfeld
Neurology 2009; 72: 1008-1015.
[Abstract]
[Full text]
[PDF]
- EDITORIALS
Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients?
- Michael S. Okun and Hubert H. Fernandez
Neurology 2009; 72: 868-869.
[Full text]
[PDF]
- ARTICLES
GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study
- A. D. Goodman, H. Rossman, A. Bar-Or, A. Miller, D. H. Miller, K. Schmierer, F. Lublin, O. Khan, N. M. Bormann, M. Yang, M. A. Panzara, A. W. Sandrock For the GLANCE Investigators
Neurology 2009; 72: 806-812.
[Abstract]
[Full text]
[PDF]
- EDITORIALS
Statins: Not just for the young or the faint of heart
- Bruce M. Coull and S. Claiborne Johnston
Neurology 2009; 72: 684-685.
[Full text]
[PDF]
- ARTICLES
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial
- E. J. Sorenson, A. J. Windbank, J. N. Mandrekar, W. R. Bamlet, S. H. Appel, C. Armon, P. E. Barkhaus, P. Bosch, K. Boylan, W. S. David, E. Feldman, J. Glass, L. Gutmann, J. Katz, W. King, C. A. Luciano, L. F. McCluskey, S. Nash, D. S. Newman, R. M. Pascuzzi, E. Pioro, L. J. Sams, S. Scelsa, E. P. Simpson, S. H. Subramony, E. Tiryaki, and C. A. Thornton
Neurology 2008; 71: 1770-1775.
[Abstract]
[Full text]
[PDF]
- EDITORIALS
Statins to treat multiple sclerosis: Friend or foe?
- Myla D. Goldman and Jeffrey A. Cohen
Neurology 2008; 71: 1386-1387.
[Full text]
[PDF]
- ARTICLES
CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial
- V. Viglietta, K. Bourcier, G. J. Buckle, B. Healy, H. L. Weiner, D. A. Hafler, S. Egorova, C.R.G. Guttmann, J. R. Rusche, and S. J. Khoury
Neurology 2008; 71: 917-924.
[Abstract]
[Full text]
[PDF]
- PATIENT PAGES
The placebo effect
- Joseph H. Friedman and Richard Dubinsky
Neurology 2008; 71: e25-26e.
[Full text]
[PDF]
- ARTICLES
Disability as an outcome in MS clinical trials
- G. C. Ebers, L. Heigenhauser, M. Daumer, C. Lederer, and J. H. Noseworthy
Neurology 2008; 71: 624-631.
[Abstract]
[Full text]
[PDF]
|
|
